For decades, cardiologists have routinely told heart failure patients to limit their daily fluid intake — a recommendation so deeply embedded in standard care that it rarely gets questioned. This systematic review, published in Heart, challenges that assumption head-on, finding no meaningful evidence that fluid restriction actually improves the outcomes patients care most about.
The review synthesized data from four randomized controlled trials — the most rigorous study design available — encompassing 682 patients across inpatient, recently discharged, and stable outpatient settings. Researchers assessed fluid restriction against liberal or unrestricted intake across outcomes including mortality, heart failure hospitalization, quality of life, thirst distress, NYHA functional class, and NT-proBNP levels. Not a single trial detected a statistically significant difference in mortality or rehospitalization rates. Quality-of-life findings were contradictory across trials, yielding no coherent signal of benefit. One consistent finding, however, was that fluid restriction reliably increased thirst distress — a meaningful burden for patients already managing a demanding treatment regimen. No significant changes in NYHA class or NT-proBNP were observed either.
The evidentiary picture here is sparse and methodologically fragile. Only one of the four included RCTs was rated at low risk of bias, and heterogeneity across trials precluded meta-analysis — meaning no pooled effect size could be calculated. With a combined sample of only 682 participants, the body of evidence is dramatically underpowered to detect modest clinical effects. That said, the consistent null findings across mortality and hospitalization, paired with documented harm in the form of increased thirst burden, is a signal cardiologists should not dismiss. This is not a story of a proven intervention whose effect size is being refined — it is a story of a widely practiced intervention whose foundational evidence simply does not exist. The practical implication for the broader heart failure population is that restrictive fluid prescriptions may impose measurable patient suffering without compensatory clinical gain, warranting urgent investment in adequately powered trials.